i
n
f
l
a
r
x
Loading
Loading
izicopan
Oral C5aR inhibitor
Phase 2 studies to be initiated
aHUS, IgAN and rapidly progressing IgAN, others
Topline Phase 2a reported
Additional indications in immuno-dermatology, hematology, neurology and others
Vilobelimab
C5a inhibitor
Approved by European Commission*
Phase 2 "Just Breathe" ASPR/BARDA clinical platform study
vilobelimab
C5a inhibitor
Phase 2 IXCHANGE & IXPLORE reported
Phase 3 reported**
IFX002
C5a inhibitor
Long-acting antibody for optimized use in I&I
*Commercial partnering and distribution options in the EU being considered.
** Phase 3 stopped early for futility at interim analysis, FDA interaction considered.
aHUS [atypical hemolytic uremic syndrome]. IgAN [immunoglobulin-A nephropathy]. C3G [anti-C3 glomerulopathy].